Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Bristol-Myers Squibb (BMS)
Scientific Title
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)